there are no firm timelines as one would suspect. the presentations used to have some form of timelines but these went "missing" on recent presentations. they have stated that they are hoping to have some of the generics ready for testing in the next 12-18 months but time will tell. and then the testing stage could take a while. slow process there and really not much to spur them on - they are not paying dividends to preserve cash, bonuses determined on internally created KPI's (that coincidentally DO NOT include the SP fluctuations), will still receive some form of payments from Eli but appears that they will retain these for their own use, and the lack of transparency quite concerning IMO.
Anyhow good luck with your discussions with company as I personally would take what is said with a grain of salt at this stage of the pipeline "production" - way too early IMO. anyhow all IMO.
and if the hexima "J/V" which appears to have been shrouded in "secrecy" (still waiting for terms of ending of the J/V, who funded what, who got any benefit of whatever was created at time of J/V finalisation, how much did ACR spend - time/resoucres/$'s - on the development of the product, etc etc) IMO is a pointer then I have no real faith in whats coming at some future stage.
Add to My Watchlist
What is My Watchlist?
